459 related articles for article (PubMed ID: 33090219)
21. Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.
Schulman AA; Howard LE; Tay KJ; Tsivian E; Sze C; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ; Polascik TJ
Cancer; 2017 Nov; 123(21):4122-4129. PubMed ID: 28662291
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancer.
Xiao WJ; Zhu Y; Zhu Y; Dai B; Ye DW
World J Urol; 2018 May; 36(5):769-774. PubMed ID: 29372356
[TBL] [Abstract][Full Text] [Related]
23. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy.
Xiao WJ; Zhu Y; Dai B; Ye DW
PLoS One; 2017; 12(11):e0187887. PubMed ID: 29121104
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Prostate Cancer Stage Groups Updated in the 8th Edition of the American Joint Committee on Cancer Tumor-Node-Metastasis Staging Manual.
Lee H; Lee M; Byun SS; Lee SE; Hong SK
Clin Genitourin Cancer; 2019 Feb; 17(1):e221-e226. PubMed ID: 30472041
[TBL] [Abstract][Full Text] [Related]
26. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
27. Modified the 8th AJCC staging system for patients with advanced prostate cancer: a study based on SEER database.
Sun C; Yang D; Zhu J; Zhou Y; Xiang C; Wu S
BMC Urol; 2022 Nov; 22(1):185. PubMed ID: 36384495
[TBL] [Abstract][Full Text] [Related]
28. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.
Cooperberg MR; Hinotsu S; Namiki M; Ito K; Broering J; Carroll PR; Akaza H
J Clin Oncol; 2009 Sep; 27(26):4306-13. PubMed ID: 19667269
[TBL] [Abstract][Full Text] [Related]
29. The risk of death from prostate cancer in men with Gleason score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapy.
Yang DD; Chen MH; Wu J; Braccioforte MH; Moran BJ; D'Amico AV
Urol Oncol; 2022 Jan; 40(1):6.e21-6.e27. PubMed ID: 34315661
[TBL] [Abstract][Full Text] [Related]
30. External validation of the cancer of the prostate risk assessment score to predict biochemical relapse after radical prostatectomy for prostate cancer in Japanese patients.
Yoshida T; Nakayama M; Takeda K; Arai Y; Kakimoto K; Nishimura K
Urol Int; 2012; 89(1):45-51. PubMed ID: 22441013
[TBL] [Abstract][Full Text] [Related]
31. Oncological Outcomes After Radical Prostatectomy for High-Risk Prostate Cancer Based on New Gleason Grouping System: A Validation Study From University of Southern California With 3,755 Cases.
Djaladat H; Amini E; Xu W; Cai J; Daneshmand S; Lieskovsky G
Prostate; 2017 May; 77(7):743-748. PubMed ID: 28144967
[TBL] [Abstract][Full Text] [Related]
32. Local Therapy Improves Survival in Metastatic Prostate Cancer.
Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
[TBL] [Abstract][Full Text] [Related]
33. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
34. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
35. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
36. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
37. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
[TBL] [Abstract][Full Text] [Related]
38. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Lin Y; DiPaola RS; Yao SL
Eur Urol; 2015 Nov; 68(5):805-11. PubMed ID: 25800944
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to sub-classify stage IV?
Abdel-Rahman O
PLoS One; 2017; 12(11):e0188450. PubMed ID: 29182656
[TBL] [Abstract][Full Text] [Related]
40. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S
Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
